Alerts
Want to monitor XBIO?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor XBIOWant to monitor XBIO?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor XBIOxenetic biosciences (nasdaq: xbio) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. xenetic's proprietary drug development platforms include polyxen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. xenetic's lead investigational product candidates include fda orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease.